Ethosuximide is a medication used to treat seizure disorders in humans. We previously demonstrated that ethosuximide could delay age-related changes and extend the life span of C. elegans. The mechanism of action of ethosuximide in life span extension is unknown, and elucidating how ethosuximide functions is important for defining endogenous processes that influence life span and for exploring the potential of ethosuximide as a therapeutic for age-related diseases. To identify factors that mediate the activity of ethosuximide, we conducted a genetic screen and identified mutations in two genes,
che-3 and
osm-3, that confer resistance to ethosuximide-mediated toxicity. Mutations in
che-3 and
osm-3 cause defects in an overlapping set of chemosensory neurons, resulting in defective chemosensation and life span extension. These findings suggest that ethosuximide extends life span by inhibiting the function of specific chemosensory neurons. This model is supported by the observation that ethosuximide treated animals displayed numerous phenotypic similarities with mutants that have chemosensory defects. Furthermore, long-lived
osm-3 animals were resistant to the life span extension caused by ethosuximide, suggesting the drug extends life span by inhibiting chemosensation. These studies demonstrate a novel mechanism of action for a life span extending drug and indicate that sensory perception has a critical role in controlling life span. Sensory perception also influences the life span of Drosophila, suggesting that sensory perception has an evolutionarily conserved role in life span control. These studies highlight the potential of ethosuximide and related drugs that modulate sensory perception to extend life span in diverse animals.